Announcements Trials
Browse Landscape

Phase

Phase 3 15Phase 2 12Phase 1/2 2Phase 2/3 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 5Endocrine 1Breast 1

Conditions

Breast Neoplasms 1

Interventions

Paclitaxel 100Trastuzumab 81pembrolizumab 78Fulvestrant 68Cyclophosphamide 66Carboplatin 49Capecitabine 47Docetaxel 45palbociclib 41Lapatinib 40Letrozole 37Doxorubicin 29olaparib 28Taxes 28Nivolumab 25Magnetic Resonance Spectroscopy 25Gemcitabine 25130-nm albumin-bound paclitaxel 25Everolimus 23Biopsy 23ribociclib 22abemaciclib 21Specimen Handling 21Albumin-Bound Paclitaxel 21Cisplatin 20Radiotherapy 19Bevacizumab 19Ado-Trastuzumab Emtansine 19pertuzumab 17Alpelisib 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Gonadotropin-Releasing Hormone × Breast × Clear all
NCT03332797 2026-05-15

A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

Genentech, Inc.

Phase 1 Active not recruiting
181 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡